Starpharma

Gain a direct line to Starpharma's leadership


Be first to know our latest company updates


Watch exclusive videos accompanying major
news

Home

Research Publications

Our Capabilities

Our Brands

Team

About Starpharma

Company

Explore our DEP® Solutions

DEP® Pipeline

DEP® Drug Delivery Platform

Dendrimer Technology

Pipeline & Products

Corporate Governance

Shareholder Services

Stock Listing

Market Data

Annual General Meeting 2025

Annual Reports

Video Library

Investor Presentations

Updates

ASX Announcements

Why Invest

Entitlement Offer

Announcements

Our People & Culture

Careers

People & Culture

Starpharma Partnerships

Star Navigator

Partnerships

Poppins

upload.jpg

As Starpharma prepares for the BIO International Convention this June, we are very engaged with the theme “The World Can’t Wait”. It’s a timely reminder that #innovation in #biotechnology is critical for shaping the future of healthcare.

Read on to discover how we’re driving innovation forward through our #dendrimer technology and collaborative approach.

Innovation is the engine that powers transformation, particularly in biotechnology, where it converts scientific discovery into life-changing therapies. It’s what drives us to ask not just “what is,” but “what if?” and “what’s next?”

At its core, innovation in the biotech and pharmaceutical sectors creates value by solving critical challenges. For Starpharma, this means leveraging our unique dendrimer technology to improve health outcomes and quality of life for patients battling significant illnesses like cancer.

Innovation in biotech is pivotal as it directly influences human lives. From pioneering drug delivery methods to groundbreaking therapies, biotech innovation reshapes health outcomes globally. For patients, especially those with rare or currently untreatable conditions, biotech innovation signifies hope and the promise of new treatments that can significantly improve quality of life and even save lives.

Starpharma has a rich history of innovation, and like many biotech companies, our success depends on our ability to innovate in novel therapeutic areas. Founded as a spin-off from CSIRO, Starpharma leverages the potential of dendrimers, which are highly-branched, tree-like, nanoscale polymers, to improve the efficacy, safety, and targeting of cancer therapies.

Over the years, our research has evolved from developing dendrimer-based products for antiviral applications, including HIV, STIs, and bacterial vaginosis (BV), to refining our proprietary technology for enhanced drug delivery, with a focus on oncology. We have made significant strides in advancing dendrimer-based products through preclinical and clinical trials and collaborating with international companies to explore dendrimer applications in drug delivery and other medical areas.

More recently, Starpharma has generated extensive clinical validation of its dendrimer-enhanced product (DEP®) platform through the clinical development of multiple DEP® candidates. We’ve advanced the dendrimer technology in a way that allows for improved targeting of drugs, minimising systemic exposure and side effects while maximising therapeutic benefit. More than 350 patients have been treated with Starpharma’s DEP® drug delivery technology across multiple clinical oncology programs, generating valuable data.

Today, we continue to innovate and explore novel therapeutic areas, with an emphasis on cancer diagnosis and treatment.

We approach innovation through three core pillars:

➡️ Patient-Centred Design: Every project begins with the question: How will this benefit the patient? This ensures that our R&D efforts are always anchored in real-world impact.

➡️ Agility and Adaptability: We aim to move quickly, accelerating where possible, and smartly in a constantly evolving landscape. Our teams are structured to pivot as new data emerges, enabling faster iteration and more effective decision-making.

➡️ Collaborative Intelligence: We actively seek diverse perspectives within our teams and with our external stakeholders, including partners, key opinion leaders, and physicians. Innovation thrives when cross-disciplinary minds come together with a shared mission.

With this approach, we aim to ensure that our scientific and strategic innovations don’t just look good in theory, they deliver results in practice.

With a strong heritage in R&D partnerships with top-tier companies such as Genentech, MSD, AstraZeneca and others, Starpharma offers a flexible suite of partnering models to accelerate drug development using its DEP® dendrimer platform. 

From strategic alliances and spinouts to licensing and R&D collaborations, partners can access tailored support—from early-stage validation to full-scale commercialisation. 

Whether you're looking to co-develop assets, license DEP® technology, or fast-track your pipeline, Starpharma provides the expertise and infrastructure to bring innovative therapies to market.

Navigating Innovation in Biotech: Enhancing Patient Outcomes Through Discovery and Collaboration